Corporate Overview

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2009 sales of $12.6 billion and has approximately 49,700 employees.

About Baxter Australia and New Zealand

Baxter Healthcare has invested heavily in the Australia and New Zealand (ANZ) region for over 45 years.

Australian operations commenced in 1963 and now comprise a manufacturing plant in Western Sydney; distribution and warehousing depots in NSW, QLD, VIC, SA, WA and TAS; and aseptic compounding facilities in NSW, QLD, VIC, WA and SA.

New Zealand operations commenced in 1980 and include a head office in Auckland; warehouse and distribution centres in Auckland and Christchurch; and aseptic compounding pharmacies in Auckland, Waikato and Christchurch.

Quality & Innovation

Beginning more than 75 years ago, Baxter has been heavily involved in many medical breakthroughs we take for granted today: intravenous medicine, kidney dialysis, blood component therapy and haemophilia care.

Baxter 'firsts' include:

  • The first manufactured IV solution
  • The first blood storage system
  • The first commercial artificial kidney
  • The first needleless IV system
  • The first clotting factor for haemophilia
  • The first portable dialysis therapy

Baxter Business

  • The BioScience business unit is a leading manufacturer of plasma-based and recombinant proteins used to treat haemophilia, and other biopharmaceutical products, including plasma-based therapies to treat immune disorders, alpha-1 antitrypsin deficiency and other chronic blood-related conditions; biosurgery products for haemostasis, wound-sealing and tissue regeneration; and vaccines. The business also manufactures manual and automated blood and blood-component separation and collection systems.

  • The Medication Delivery business is a leading manufacturer of products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, infusion pumps, and inhaled anesthetics, as well as products and services related to drug formulation and enhanced packaging technologies.

  • The Renal business unit is a leading manufacturer of products for peritoneal dialysis (PD), a home therapy for people with end-stage renal disease, or irreversible kidney failure. These products include a range of PD solutions and related supplies to help patients safely perform fluid exchanges, as well as automated PD cyclers that perform solution exchanges for patients overnight while they sleep. The business also distributes products (haemodialysis instruments and disposables, including dialyzers) for haemodialysis, a form of dialysis generally conducted several times a week in a hospital or clinic.

  • The Baxter Pharmacy Services business provides TGA regulated aseptic compounding services, for hospital pharmacies throughout Australia and New Zealand.   Products include chemotherapy, antibiotics, analgesics for pain relief and intravenous nutrition.  Approximately 300 pharmacy staff are employed by Baxter across Australia and New Zealand in nine compounding facilities. All of Baxter's facilities are TGA/Medsafe approved and audited.
  • Links

    Baxter is committed to ethical operations and so undertakes all business activities in line with leading industry regulatory bodies including: